Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Intrinsic resistance to anti-HER2 therapy in breast cancer remains an obstacle in the clinic, limiting its efficacy. However, the biological basis for intrinsic resistance is poorly understood. Here we performed a CRISPR/Cas9-mediated loss-of-function genetic profiling and identified TALDO1, which e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yi, Gong, Chang, Huang, De, Chen, Rui, Sui, Pinpin, Lin, Kevin H., Liang, Gehao, Yuan, Lifeng, Xiang, Handan, Chen, Junying, Yin, Tao, Alexander, Peter B., Wang, Qian-Fei, Song, Er-Wei, Li, Qi-Jing, Wood, Kris C., Wang, Xiao-Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189078/
https://www.ncbi.nlm.nih.gov/pubmed/30323337
http://dx.doi.org/10.1038/s41467-018-06651-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189078/
https://www.ncbi.nlm.nih.gov/pubmed/30323337
http://dx.doi.org/10.1038/s41467-018-06651-x

Ejemplares similares